Sun Pharmaceuticals Industries announced that one of its wholly owned
subsidiaries has entered into a licensing agreement with a subsidiary of China Medical System
Holdings for the development and commercialization of Tildrakizumab, an innovative
biologic product, for psoriasis and psoriatic arthritis in Greater China (including Mainland China,
Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan).
Under terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential. CMS will be responsible for development, regulatory filings and commercialization of the product in China. The initial tenure of the agreement shall be 15 years from the first commercial sale of Tildrakizumab in Greater China, and may be extended for additional 3 years' subject to certain conditions defined in the agreement.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
